AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-13732006_ITM" title="Facts and information about Genaera Announces Interim EVIZON(TM) Phase II (MSI-1256F-209) Data.">Genaera Announces Interim EVIZON(TM) Phase II (MSI-1256F-209) Data.</a>
Close
Set up an RSS feed that alerts you when new articles from PR Newswire are available.
Frequently asked questions about RSS feeds
Genaera Announces Interim EVIZON(TM) Phase II (MSI-1256F-209) Data.
-- 40 mg intravenous dose safe and active in stabilizing vision in wet AMD --
-- Conference Call/Webcast Scheduled for Today at 5:00 PM EST --
PLYMOUTH MEETING, Pa., March 1 /PRNewswire-FirstCall/ -- Genaera Corporation today announced data from a 24 week interim analysis of its largest Phase II trial, MSI-1256F-209 (Study 209), of EVIZON(TM) (squalamine lactate), under development for the treatment of "wet" age-related macular degeneration (AMD). At 24 weeks of therapy, the 40 mg dose of EVIZON was safe and well tolerated and stabilized vision in both the Study Eyes and the Fellow Affected Eyes of the majority of subjects.
In Study Eyes, ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Genaera Corporation Presents Encouraging Data on Bilateral Visual Acuity in...
- Press release article from: PR Newswire March 29, 2006 700+ words
...outcomes for subjects in these studies with fellow affected eyes (i...most marked in subjects with poorer vision in fellow affected eyes, many...letters. In subjects with very poor vision in the fellow affected eye (defined...
- Genaera Corp presents encouraging data on bilateral visual acuity in subjects...
- News wire article from: Chemical Business Newsbase March 29, 2006 700+ words
...the outcomes for subjects in these studies with fellow affected eyes and poor vision...analysis of all fellow affected eyes at 24 weeks...of 3 letters. In subjects with very poor vision in the fellow affected eye, the improvement...
- Genaera Announces Positive Interim EVIZON(TM) Phase II (MSI-1256F-208) AMD Data...
- Press release article from: PR Newswire May 3, 2005 700+ words
...while study eyes among subjects in the PDT control group...Thirty-seven of the 46 subjects (80%) were diagnosed as...in both eyes. At week 9, subjects with a fellow affected eye in the EVIZON treatment...
- Genaera Presents EVIZON(TM) Overview and New Trodusquemine Data at Fortis Bank...
- Press release article from: PR Newswire April 26, 2006 700+ words
...these studies with fellow affected eyes (i.e...recent analyses of fellow affected eyes in Study 207...visual acuity in the fellow affected eyes of subjects with poorer vision...of 1995 that are subject to risks and uncertainties...
- Genaera presents Evizon overview and new trodusquemine data at Fortis Bank...
- News wire article from: Chemical Business Newsbase April 26, 2006 700+ words
...described outcomes for subjects in these studies with fellow affected eyes and poor vision...from recent analyses of fellow affected eyes in Study 207...visual acuity in the fellow affected eyes of subjects with poorer vision...
- Genaera announces positive interim Evizon Phase II (MSI-1256F-208) AMD data at...
- News wire article from: Asia Africa Intelligence Wire May 3, 2005 700+ words
...letters, while study eyes among subjects in the PDT control group lost...letters. About 37 of the 46 subjects were diagnosed as having wet AMD in both eyes. At week 9, subjects with a fellow affected eye in the Evizon treatment...
- Genaera Corporation Presents Clinical Results for EVIZON(TM) for Treatment of...
- Press release article from: PR Newswire July 18, 2005 700+ words
...improvement and 100% of the subjects had either stable or improved...OCT) data showing benefit in subjects' fellow affected eyes. Additionally, Dr. Ciulla...one-third to one- half of subjects who suffer from wet AMD in both...
- Genaera Corporation Announces Interim EVIZON(TM) Phase II (MSI-1256F-209) Data...
- News wire article from: The America's Intelligence Wire March 1, 2006 700+ words
...first of all, our subjects, were relatively naive...the disease of the subjects. One of the things...had to deal with the Fellow Affected Eye. These where eyes...and 20 mg arms in the Fellow Affected Eye. And that's...that group of 91 subjects that didn't receive...
- Genaera announces interim Evizon Phase II data.
- News wire article from: Chemical Business Newsbase March 1, 2006 700+ words
...the Study Eyes and the Fellow Affected Eyes of the majority of subjects. In Study Eyes, Evizon...included data on 108 subjects. Average age of enrolled subjects was 75 years. The most...events reported in any subject at the 24-week interim...
- /C O R R E C T I O N -- Genaera Corporation/.
- Press release article from: PR Newswire March 2, 2006 700+ words
...Corporation over PR Newswire, we are advised by the company that the last sentence of the ninth paragraph, "No Fellow Affected Eyes from subjects in any dosage group lost fifteen letters or greater," was inadvertently inserted and should be deleted...
Source: HighBeam Research, Genaera Announces Interim EVIZON(TM) Phase II (MSI-1256F-209) Data.